Cargando…

Changing trends of hospitalisation of liver cirrhosis in Beijing, China

OBJECTIVE: To examine if the hospitalisation trends of liver cirrhosis are changing with the changes of risk factors of the disease in China. DESIGN: Secondary analysis of hospitalisation records in the 31 top-ranking hospitals in Beijing. RESULTS: Between 2006 and 2010, hospitalisation from viral h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bao, Xiao-Yuan, Xu, Bei-Bei, Fang, Kai, Li, Yan, Hu, Yong-Hua, Yu, Guo-Pei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650903/ https://www.ncbi.nlm.nih.gov/pubmed/26629359 http://dx.doi.org/10.1136/bmjgast-2015-000051

Ejemplares similares

Lower survival and higher rates of cirrhosis in patients with ROUX-EN-Y gastric bypass hospitalised with alcohol-associated hepatitis
por: Anugwom, Chimaobi, et al.
Publicado: (2023)

Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial
por: Kimer, Nina, et al.
Publicado: (2020)

HBV infection-induced liver cirrhosis development in dual-humanised mice with human bone mesenchymal stem cell transplantation
por: Yuan, Lunzhi, et al.
Publicado: (2019)

Aflatoxin B(1) exposure and liver cirrhosis in Guatemala: a case–control study
por: Alvarez, Christian S, et al.
Publicado: (2020)

Value and risk of percutaneous liver biopsy in patients with cirrhosis and clinical suspicion of autoimmune hepatitis
por: Sripongpun, Pimsiri, et al.
Publicado: (2021)

Plasminogen activator inhibitor is significantly elevated in liver transplant recipients with decompensated NASH cirrhosis
por: Rivas, Gloriany, et al.
Publicado: (2021)

Efficacy of antiviral therapy in patients with post-hepatitis C liver cirrhosis: is hyperuricaemia a potential adverse effect?
por: Elsayed, Amr, et al.
Publicado: (2020)

Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation
por: Monteiro, Sofia, et al.
Publicado: (2021)

The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa
por: Lemoine, Maud, et al.
Publicado: (2016)

Study protocol for a randomised controlled trial of carvedilol versus variceal band ligation in primary prevention of variceal bleeding in liver cirrhosis (CALIBRE trial)
por: Tripathi, Dhiraj, et al.
Publicado: (2019)

Opioid and benzodiazepine prescription among patients with cirrhosis compared to other forms of chronic disease
por: Konerman, Monica A, et al.
Publicado: (2019)

Bacteraemia, sepsis and antibiotic resistance in Australian patients with cirrhosis: a population-based study
por: Johnson, Amy L, et al.
Publicado: (2021)

Negative impact of the pandemic on hospital admissions, morbidity and early mortality for acute cirrhosis decompensation
por: Gananandan, Kohilan, et al.
Publicado: (2023)

Trends in indirect liver function marker testing in Wales from 2000 to 2017 and their association with age and sex: an observational study
por: Hill, Trevor Alexander, et al.
Publicado: (2022)

Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies
por: Middleton, Paul, et al.
Publicado: (2021)

Factors associated with renal dysfunction in hepatitis C-related cirrhosis and its correlation with Child-Pugh score
por: Bhatti, Hamza Waqar, et al.
Publicado: (2019)

Acute kidney injury after multiphase imaging for lesions detected on hepatocellular carcinoma surveillance in patients with cirrhosis
por: Khan, Adnan Aman, et al.
Publicado: (2020)

Development of a national Department of Veterans Affairs mortality risk prediction model among patients with cirrhosis
por: Koola, Jejo David, et al.
Publicado: (2019)

Evaluating clinical outcomes and prognosis in patients with cirrhosis and portal hypertension: a retrospective observational cohort study
por: Lee, Nerissa Hoi Ching, et al.
Publicado: (2023)

Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial)
por: de Wit, K, et al.
Publicado: (2020)

Trends of hospitalisation for patients with liver cirrhosis in Ningxia, China: a cross-sectional study
por: Shi, Chao, et al.
Publicado: (2023)

Non-selective β-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function
por: Blasco-Algora, Sara, et al.
Publicado: (2016)

PNPLA3 gene predicts clinical recovery after sustained virological response in decompensated hepatitis C cirrhosis
por: Dunn, Winston, et al.
Publicado: (2019)

A potential novel inflammation biomarker for predicting the prognosis of decompensated liver cirrhosis
por: Xie, Yanan, et al.
Publicado: (2022)

Neuroimmunomodulation of adrenoblockers during liver cirrhosis: modulation of hepatic stellate cell activity
por: Medina Pizaño, Mariana Yazmin, et al.
Publicado: (2023)

Characterisation of blood microbiota in patients with liver cirrhosis
por: Kajihara, Mikio, et al.
Publicado: (2019)

Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis
por: Tran, Sally Ann, et al.
Publicado: (2018)

Predicting 1-year mortality among patients with decompensated cirrhosis: results of a multicentre evaluation of the Bristol Prognostic Score
por: Bowers, Sarah Pauline, et al.
Publicado: (2022)

Suppressor CD4(+) T cells expressing HLA-G are expanded in the peripheral blood from patients with acute decompensation of cirrhosis
por: Khamri, Wafa, et al.
Publicado: (2022)

Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET)
por: Weiss, Emmanuel, et al.
Publicado: (2023)

A new model predicts hepatocellular carcinoma in patients with HBV-related decompensated liver cirrhosis and long-term antiviral therapy: a prospective study
por: Mao, Hao-dan, et al.
Publicado: (2023)

Changing epidemiology of cirrhosis from 2010 to 2019: results from the Global Burden Disease study 2019
por: Xiao, Shiyu, et al.
Publicado: (2023)

Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion
por: Weersink, Rianne A, et al.
Publicado: (2016)

Liver cirrhosis in England—an observational study: are we measuring its burden occurrence correctly?
por: Ratib, Sonia, et al.
Publicado: (2017)

Three-dimensional bioprinted hepatorganoids prolong survival of mice with liver failure
por: Yang, Huayu, et al.
Publicado: (2021)

Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study
por: Buch, Stephan, et al.
Publicado: (2023)

Antiviral therapy effectively improves liver hemodynamics as evidenced by serum biomarker and contrast-enhanced ultrasound examinations in patients with hepatitis B cirrhosis
por: Xu, Xiaoyong, et al.
Publicado: (2018)

A decision tree model to predict liver cirrhosis in hepatocellular carcinoma patients: a retrospective study
por: Zhou, Zheyu, et al.
Publicado: (2023)

Less liver fibrosis marker increment in overweight chronic hepatitis B patients observed by age-adjusted Fibrosis-4 Index
por: Liu, Ta-Wei, et al.
Publicado: (2020)

Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance
por: Meng, Chao-Yang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e9kafc2t9srbjlv0tmqis7tsqm